Role of uric acid in metabolic syndrome

Uric Acid: Biology, Functions and Diseases

Volumn , Issue , 2012, Pages 57-76

  Simão, Andréa Name Colado ^a   Dichi, Isaias ^a  

^a UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857411893     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (77)

1. Alper Jr, A.B.; Chen, W.C.; Yau, L.; Srinivasan, S.R.; Berenson, G.S.; Hamm, L.L. Childhood uric acid predicts adult blood pressure (2005). The Bogalusa Heart Study. Hypertension, 45, 34-38.
2. Ames, B.N.; Cathcart, R.; Schwiers, E.; Hochstein, P. (1981) Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci Usa,. 78, 6858-6862.
3. Arita, Y.; Kihara, S.; Ouchi, N.; Takahashi, M.; Maeda, K.; Miyagawa, J.; Hotta, K.; Shimomura, I.; Nakamura, T.; Miyaoka, K.; Kuriyama, H.; Nishida, M.; Yamashita, S.; Okubo, K.; Matsubara, K.; Muraguchi, M.; Ohmoto, Y.; Funahashi, T.; Matsuzawa, Y. (1999). Paradoxal decrease of an adipose-specific protein, adiponectin in obesity. Biochem Biophys Res Commun, 257, 79-83.
4. Asl, S.Z.; Ghasemi, A.; Azizi, F. (2008). Serum nitric oxide metabolites in subjects with metabolic syndrome. Clin Biochem, 41, 1342-1347.
5. Augusto, O.; Bonini, M. G.; Amanso, A. M.; Linares, E.; Santos, C. C. X.; de Menezes, S. L. (2002). Nitrogen dioxide and carbonate radical anion: two emerging radicals in biology. Free Radic Biol. Med, 32, 841-859.
6. Bedir, A.; Topbas, M.; Tanyeri, F.; Alvur, M.; Arik, N. (2005). Leptin might be a regulator of serum uric acid concentration in humans. Jpn Heart J, 44, 527-536.
7. Cannon, P.J.; Stason, W.B.; Demartini, F.E.; Sommers, S.C.; Laragh, J.H. (1966). Hypeuricemia in primary and renal hypertension. N Engl J Med, 275, 457-464.
8. Cecchini, R.; Aruoma, O.I.; Halliwell, B. (1990). The action of hydrogen peroxide on the formation of thiobarbituric acid-reactive material from microsomes or from DNA damage by bleomycin or o-phenanthroline. Artefacts in the thiobarbituric acid test. Free Rad Res Commun, 10,:245-258.
9. Choi, H.K.; Ford, E.S. (2007). Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med, 120, 442-447.
10. Choi, H.K.; Mount, D.B.; Reginato, A.M. Pathogenesis of gout. (2004). Ann Inter Med, 143, 499-516.
11. Choi, J.W.; Ford, E.S.; Gao, X.; Choi, H.K. Sugar sweetened soft drinks, diet soft drinks, and serum acid level: The Third National Health and Nutrition Examination Survey. (2008). Arthritis Rheum 59, 109-116.
12. Cook, S.; Hugli, O.; Egli, M.; Vollenweider, P.; Brucelin, R.; Nicod, P.; Thorens, B.; Scherrer, U. (2003). Clustering of cardiovascular risk factors mimicking the human metabolic syndrome. Swiss Med Wkly, 133, 360-3.
13. Culleton, B,F,; Larson, M.G.; Kannel, W.B.; Levy, D. (1999). Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med, 131, 7-13.
14. Facchini, F.; Chen, I.; Hollenbeck, C.B.; Reaven, G.M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric concentration. (1991). JAMA, 266, 3008-3011.
15. Fang, J.; Alderman, M.H. (2000). Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA, 283, 2404-2410.
16. Feig, D.I.; Kang, D.H.; Johnson RJ. (2008). Uric acid and cardiovascular disease. NEJM, 359, 1811-1821.
17. Festa, A.; D'Agostino, Jr. R.; Howard, G.; Mykkänen, L.; Tracy, R.P.; Haffner, S.M. (2000). Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 102, 42-47.
18. Ford, E.S.; Li, C.; Cook, S.; Choi, H.K. (2007). Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation, 115, 2526-2532.
19. Forstemann, U. (2006). Janus-faced role of endothelial NO synthase in vascular disease: Uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem, 387, 1521-1533.
20. Gagliardi, A.C.M.; Miname, M.H.; Santos, R.D. (2009). Uric acid: a marker of increased cardiovascular risk. Atherosclerosis, 202, 11-17.
21. George, J.; Carr, E.; Davies, J.; Belch, J.J.F.; Stuthers, A. (2006). High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation, 114, 2508-2516.
22. George, J.; Stuthers, A.D. (2009). Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag, 5, 265-272.
23. Gercsh, C.; Palii, S.P.; Kim, K.M.; Angerhofer, A.; Johnson, R.J.; Henderson, G.N. (2008). Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids, 27, 967-978.
24. Gunnett, C.A.; Heistad, D.D.; Faraci, F.M. (2003). Gene target mice reveal a critical role for inducible nitric oxide synthase in vascular dysfunction during diabetes. Stroke, 34, 2970-2974.
25. Haffner, S.M. (2003). Insulin resistance, inflammation and the prediabetic state. Am J Cardiol 92, 18-26J.
26. Halliwell, B.; Gutteridge, J.M.C. Antioxidant protection by compounds synthesized in vivo, third ed., Oxford University Press, New York., page 19, 197, 1999.
27. Hayden, M.R.; Tyagi, S.C. (2004). Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and the diabetes mellitus: The urate redox shuttle. Nutrition and Metabolism, 1, 1-10- .
28. Ho, W-J.; Tsai, W-P.; Yu, K-H.; Tsay, P-K.; Wang, C-L.; Hsu, T-S.; Kuo, C-T. (2010). Association between endothelial function and hyperuricemia. Rheumatology, 49, 1929-1934.
29. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Maeda, K.; Nishida, M.; Kihara, S.; Sakai, N.; Nakajima, T.; Hasegawa, K.; Muraguchi, M.; Ohamoto, Y.; Nakamura, T.; Yamashita, S.; Hanafusa, T.; Matsuzawa, Y. (2000). Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Artherioscler Thromb Vasc Biol, 20, 1595-1599.
30. Hotta, K.; Funahashi, T.; Bodkin, N.L.; Ortmeyer, H.K.; Arita, Y.; Hansen, B.C.; Matsuzawa, Y. (2001). Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progress to type 2 diabetes in rhesus monkeys. Diabetes, 50, 1126-1133.
31. Hovind, P.; Rossing, P.; Tarnow, L.; Johnson, R.J.; Parving, H.H. (2009). Serum acid uric as a predictor for development of diabetic nephropathy in type 1 diabetes. Diabetes, 58, 1668-1671.
32. Imaram, W.; Gersch, C.; Kim, K.M.; Johnson, R.J.; Henderson, G.N.; Angerhofer, A. (2010). Radicals in the reaction between peroxynitrite and uric acid identified by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. Free Radic Biol Med, 49, 275-281.
33. Iwashima, Y.; Katsuya, T.; Ishikawa, K.; Ouchi, N.; Ohishi, M.; Sugimoto, K.; Fu, Y.; Motone, M.; Yamamoto, K.; Matsuo, A.; Ohashi, K.; Kihara, S.; Funahashi, T.; Rakugi, H.; Matsuzawa, Y.; Ogihara, T. (2004). Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension, 43, 1318-1323.
34. Johnson, R.J.; Feig, D.I.; Herrera-Acosta, J.; Kang, D-H. (2005a). Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension, 45, 18-20.
35. Johnson, R.J.; Herrera-Acosta, J.; Screiner, GF.; Rodriguez-Iturbe, B. (2002a). Subtle acquired renal injury as a mechanism of salt sensitive hypertension. N Engl J Med, 346, 913-923.
36. Johnson, R.J.; Rodriguez-Iturbe, B.; Kang, D-H.; Feig, D.I.; Herrera-Acosta, J. (2005b). A unifying pathway for essential hypertension. Am J Hypertens, 18, 431-440.
37. Kanellis, J.; Kang, D.H. (2005). Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Sem Nephrol, 25, 39-43.
38. Kern, P.A.; Ranganathan, S.; Li, C.; Wood, L.; Ranganathan, G. (2001). Adipose tissue tumor necrosis factor and IL-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab, 280, E745-751.
39. Khosla, U.M.; Zharikov, S.; Finch, J.L.; Nakagawa, T.; Roncal, C.; Mu, W.; Krotova, K.; Block, E.R.; Prabhakar, S.; Johnson, RJ. (2005). Hyperuricemia induces endothelial dysfunction. Kidney Intern, 67, 1739-1742.
40. Koprovski, H.; Spitsin, S.V.; Hooper, D.C. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. [2001]. Ann Neurol, 49:139.
41. Kuzkaya, N.;Weissmann, N.; Harrison, D. G.; Dikalov, S. (2005). Interactions of peroxynitrite with uric acid n the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol, 70, 343-354.
42. Lin, K.C.; Tsao, H.M.; Chen, C.H.; Chou, P. (2004). Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia. J Rheumatol, 31, 1152-1158.
43. Maeda,, N.; Takahashi, M.; Funahashi, Y.; Kihara, S.; Nishizawa, H.; Kishida, K.; Nagaretani, H.; Matsuda, M.; Komuro, R.; Ouchi, N.; Kuriyama, H.; Hotta, K.; Nakamura, T.; Shimomura, I.; Matsuzawa, Y. (2001). PPAR-γ ligands increase expression and plasma concentration of adiponectin, an adipose-driven protein. Diabetes, 50, 2094-2099.
44. Maxwell, S.R.; Thomason, H.; Sandler, D.; LeGuen, C.; Baxter, M.A.; Thorpe, G.H.; Jones, A.F.; Barnett, A.H. (1997). Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest, 27, 484-490.
45. Mazzali, M.; Hughes, J.; Kim, Y.G.; Jefferson, J. A.; Kamg, D-H.; Gordon, K.L.; Lan, H.Y.; Kivlighn, S.; Johnson, R.J. (2001). Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension, 38, 1101-1106.
46. Mené, P.; Punzo, G. (2008). Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens, 26, 2085-2092.
47. Mercuro, G.; Vitale, C.; Cerquetani, E.; Zancu, S.; Deidda, M.; Fine, M.; Rosano, G.M.C. (2004). Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cadiol, 94, 932-935.
48. Molnár, D.; Decsil, T.; Koletzko, B. (2004). Reduced antioxidant status in obese children with multimetabolic syndrome. Intern J Obesity, 28, 1197-1202.
49. Muscelli, E.; Natali, A.; Bianchi, S.; Bigazzi, R.; Galvan, A.Q.; Sironi, A.M.; Franscerra, S.; Ciociaro, D.; Ferrannini, E. (1996) Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens, 9, 746-752.
50. Nakagawa, T.; Hu, H.; Zharikov, S.; Tutle, K.R.; Short, R.A.; Glushakova, O.; Ouyang, X.; Feig, D.I.; Block, E.R.; Herrera-Acosta, J.; Patel, J.M.; Johnson, R.J. (2006). A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 290, F625-631.
51. Nathan C. (1997). Inducible nitric oxide synthase: what difference does it make? J Clin Invest, 100, 2417-2423.
52. Nieto, F.J.; Iribarren, C.; Gross, M.D.; Comstock., G.W.; Cutler, R.G. (2000). Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis, 148, 131-139.
53. Niskanen, L.K.; Laaksonen, D.E.; Nyyssonen, K.; Alfthan, G.; Lakka, H.M.; Lakka, T.A.,; Salonen, J.T. (2004). Uric acid level as a risk for cardiovascular and all-mortality in middle-age men: a prospective cohort study. Arch Intern Med, 164, 1546-1551.
54. Onat, H.; Uyarel, H.; Hergenç, G.; Karabulut, A.; Albayrak, S.; Sari, I.; Yazici, M.; Keles, I. (2006). Serum acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19, 1055-1062.
55. Ouchi, N.; Kihara, S.; Arita, Y.; Okamoto, Y.; Maeda, K.; Kuriyama, H.; Hotta, K.; Nishida, M.; Takahashi, M.,; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. (1999). Novel modulator for endothelial adhesión molecules: Adipocyte-derived plasma protein adiponectin. Circulation, 100, 2473-2476.
56. Ouchi, N.; Kihara, S.; Arita, Y.; Okamoto, Y.; Maeda, K.; Kuriyama, H.; Hotta, K.; Nishida, M.; Takahashi, M.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. (2000). Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation, 102, 1296-1301.
57. Patel, D.A.; Srinivasan, S.R.; Xu, J.H..; Chen, W.; Berenson, G.S. (2006). Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study. Metab Clin Exp, 55, 1551-7.
58. Sánchez-Lozada, L.G.; Nakagawa, T.; Kang, D-H; Feig, D.I.; Franco, M.; Johson, R.J.; Herrera-Acosta, J. (2006). Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens, 15, 30-33.
59. Sanchéz-Lozada, L.G.; Tapia, E.; Bautista-Garcia, P.; Soto, V.; Ávila-Casado, C.; Veja-Campos, I.P.; Nakagawa, T.; Zhao, L.; Franco, M.; Johnson, R.J. (2008). Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 294, F710-718.
60. Santaniemi, M.; Kesäniemi, Y.A.; Ukkola, O. (2006). Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocr, 155, 745-750.
61. Santos, A.C.; Lopes, C.; Guimarães, J.T.; Barros, H. (2005). Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Intern J Obes, 29, 1452-1456.
62. Sautin, Y.Y.; Nakagawa, T.; Zharikov, S.; Johnson, R.J. (2007) Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress Am J Physiol Cell Physiol, 293, C584-596.
63. Simão, A.N.C.; Dichi, J.B.; Barbosa, D.S.; Cecchini, R.; Dichi, I. (2008). Influence of uric acid and γ-glutamyltransferase on total antioxidant capacity and oxidative stress in patients with metabolic syndrome. Nutrition, 24, 675-681.
64. Simão, A.N.C.; Lozovoy, M.A.B.; Simão, T.N.C.; Morimoto, H.K.; Dichi, I. (in press). Adiponectinemia is associated with uricemia but not with proinflammatory status in women with metabolic syndrome. J Nutr Metab.
65. Sundström, J.; Sullivan, L.; D'Agostino, R.B.; Levy, D.; Kannel, W.B.; Vasan, R.S. (2005). Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension, 45, 28-33.
66. Szabo, C.; Ischiropoulos, H.; Radi, R. (2007). Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discovery 6, 662-680.
67. Tamakoshi, K.; Yatsuya, H.; Kondo, T.; Hori, Y.; Ishikawa, M.; Zhang, H.; Murata, C.; Otsuka, R.; Zhu, S.; Toyoshima, H. (2003). The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord, 27, 443-449.
68. Trayhurn, P.; Wood, I.S. (2004). Adipokines: inflammation and the pleiotropic role of the white adipose tissue. Br J Nutr, 92, 347-355.
69. Tsouli, S.G.; Liberopoulos, E.N.; Mikhailidis, D.P.; Athyros, V.G.; Elisaf, M.S. (2006). Elevated uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metab Clin Exp 55, 1293-1301.
70. Waring, W.S.; Webb, D.J.; Maxwell, S.R.J. (2000). Uric acid as a risk factor for cardiovascular disease. Q J Med, 93, 707-713.
71. Watanabe, S.; Kang, D-H.; Feng, L.; Nakagawa, T.; Kannelis, L.; Lan, H.; Mazzali, M.; Johnson, R.J. (2002b). Uric acid, hominoid evolution, and the pathogenesis salt-sensitivity. Hypertension, 40, 355-360.
72. Williams, I.L.; Wheatcroft, S.B.; Shah, A.M.; Kearney, M.T. (2002). Obesity, atherosclerosis and the vascular endothelium: mechanism of reduced nitric oxide bioavailability in obese human. Int J Obes, 26, 754-764.
73. Xydaki AM, Case CC, Jones PH, Hoogeveen RC, Liu M, O'Brian SE.; Nelson, K.W.; Ballantyne, C.M. (2004). Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab, 89, 2697-2703.
74. Yiginer, O.; Ozcelik, F.; Inanc, T.; Aparci, M.; Ozmen, N.; Cingozbay, B.Y.; Kardesoglu, E.; Suleymanoglu, S.; Sener, G.; Cebeci, B. (2008). Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol, 97, 334-340.
75. Yokota, T.; Oritani, K.; Takahashi, I.; Ishikawa, J.; Matsuyama, A.; Ochi, N.; Kihara, S.; Funashi, T.; Tenner, A.J.; Tomiyama, Y.; Matsuzawa, Y. (2000). Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of mielomonocytic progenitors and the functions of the macrophages. Blood, 96, 1723-1732.
76. Yoo, T.W.; Sung, K.C.; Shin, H.S.; Kim, B.J.; Kim, B.S.; Kang, J.H.; Lee, M.H.; Park, J.R.; Kim, H. Rhee, E.J.; LEE, w.y.; Kim, S.W.; Ryu, S.H.; Keum, D.G. (2005). Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Cir J, 69, 928-933.
77. Zavaroni, I.; Mazza, S.; Fantuzzi, M.; Dall'Aglio, E.; Bonora, E.; Delsignore, R.; Passeri, M.; Reaven, G.M. (1993). Changes in insulin and lipid metabolism in males with asymptomatic hypeuricaemia. J Intern Med, 234, 25-30.